

Literatura ACTA MEDICINAE Speciál 2020 Karcinom prsu

- 2 **Epidemiologie karcinomu prsu**
doc. MUDr. Tomáš Büchler, Ph.D. Onkologická klinika 1. LF UK a Thomayerovy nemocnice, Praha
- 2 **Testování prediktivních markerů – současný stav**
prof. MUDr. Aleš Ryška, Ph.D. Fingerlandův ústav patologie LF UK a FN Hradec Králové
- 2 **Personalizovaná medicína – budoucnost prediktivního testování u karcinomu prsu**
prof. MUDr. Pavel Dundr, Ph.D. Ústav patologie 1. LF UK a VFN, Praha
- 2 **Změna pohledu na testování mutací *BRCA 1* a *BRCA 2* v onkologické praxi**
doc. MUDr. Lenka Foretová, Ph.D. Oddělení epidemiologie a genetiky nádorů Masarykova onkologického ústavu, Brno
- 3 **Současné možnosti chirurgické léčby karcinomu prsu**
MUDr. Jana Mergancová Chirurgická klinika Nemocnice Pardubického kraje, a. s., Pardubická nemocnice
- 3 **Rekonstrukce prsů implantáty**
MUDr. Lucie Zárubová | MUDr. Matěj Patzelt Klinika plastické chirurgie, Fakultní nemocnice Královské Vinohrady, Praha
- 3 **Adjuvantní radioterapie časného karcinomu prsu v roce 2020**
doc. MUDr. Renata Soumarová, Ph.D. | MUDr. Lenka Rušinová Radioterapeutická a onkologická klinika FN KV a 3. LF UK, Praha
- 3 **Zobrazovací metody v diagnostice karcinomu prsu**
MUDr. Regína Šírová Mammacentrum Medicon, Praha
- 4 **Neoadjuvantní a adjuvantní terapie u časného HER2 pozitivního karcinomu prsu**
MUDr. Adam Paulík Klinika onkologie a radioterapie LF UK a FN Hradec Králové
- 4 **Systémová léčba pokročilého HER2 pozitivního karcinomu prsu**
MUDr. Lenka Rušinová | doc. MUDr. Renata Soumarová, Ph.D. Radioterapeutická a onkologická klinika FN KV a 3. LF UK, Praha
- 5 **Adjuvantní léčba hormonálně pozitivního HER2 negativního časného karcinomu prsu**
MUDr. Katarína Petráková, Ph.D. Klinika komplexní onkologické péče Masarykova onkologického ústavu, Brno
- 5 **Aktuální možnosti léčby HR pozitivního a HER2 negativního metastatického karcinomu prsu**
MUDr. Markéta Palácová Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno
- 6 **Léčba časného triple negativního karcinomu prsu**
MUDr. Vlastimila Čmejlová Onkologická klinika 2. LF UK a FN v Motole, Praha
- 6 **Novinky v léčbě metastatického triple negativního karcinomu prsu**
MUDr. Miloš Holánek Klinika komplexní onkologické péče Masarykova onkologického ústavu, Brno
- 6 **Zárodečná mutace *BRCA* jako nový léčebný cíl**
prof. MUDr. Petra Tesařová, CSc. Onkologická klinika 1. LF UK a VFN, Praha
- 6 **Naděje tam, kde nebývala – imunoterapie u metastatického triple negativního karcinomu prsu**
prof. MUDr. Jindřich Fínek, Ph.D. Onkologická a radioterapeutická klinika FN a LF UK, Plzeň
- 7 **Další možnosti léčby a zlepšení péče o pacientky s hormonálně pozitivním karcinomem prsu – výhled do budoucna**
MUDr. Zuzana Bielčíková, Ph.D. Onkologická klinika VFN a 1. LF UK, Praha
- 8 **Další možnosti léčby a zlepšení péče o pacienty s HER2 dependentním karcinomem prsu – výhled do budoucna**
prof. MUDr. Luboš Petruželka, CSc. Onkologická klinika 1. LF UK VFN a ÚVN, ÚRO NNB, IPVZ, Praha

Epidemiologie karcinomu prsu

doc. MUDr. Tomáš Büchler, Ph.D. Onkologická klinika 1. LF UK a Thomayerovy nemocnice, Praha

- Mužik, J. – Šnajdrová, L. – Gregor, J.: Epidemiologie karcinomu prsu v České republice. Dostupné z: <https://www.mamo.cz/cs/lekari/epidemiologie-karcinomu-prsu/>, vyhledáno 13. 8. 2020.
- Dušek, L. – Mužik, J. – Kubásek, M., et al.: Epidemiologie zhoubných nádorů v České republice [online]. Masarykova univerzita, Brno 2005. Dostupné z: www.svod.cz, vyhledáno 13. 8. 2020.
- Malvezzi, M. – Carioli, G. – Bertuccio, P., et al.: European cancer mortality predictions for the year 2019 with focus on breast cancer. *Ann Oncol*, 2019, 30, s. 781–787.
- Katz, J.: Breast Cancer Risk Factors. Dostupné z: <http://emedicine.medscape.com/article/1945957-overview>, update 8. 4. 2020, vyhledáno 13. 8. 2020.
- PDQ Screening and Prevention Editorial Board. Breast Cancer Prevention (PDQ®) Health Professional Version. Dostupné z: <https://www.ncbi.nlm.nih.gov/books/NBK65884/>, publikováno 29. 4. 2020, vyhledáno 13. 8. 2020.
- Parise, C. A. – Caggiano, V.: Risk factors associated with the triple-negative breast cancer subtype with infourrace/ethnicities. *Breast Cancer Res Treat*, 2017, 163, s. 151–158.
- Ma, H. – Ursin, G. – Xu, X., et al.: Reproductive factors and the risk of triple-negative breast cancer in white women and African-American women: a pooled analysis. *Breast Cancer Res*, 2017, 19, s. 6.
- Ellingjord-Dale, M. – Vos, L. – Tretli, S., et al.: Parity, hormones and breast cancer subtypes – results from a largenest case-control study in a national screening program. *Breast Cancer Res*, 2017, 19, s. 10.
- Li, H. – Sun, X. – Miller, E., et al.: BMI, reproductive factors, and breast cancer molecular subtypes: A case-control study and meta-analysis. *J Epidemiol*, 2017, 27, s. 143–151.
- Phipps, A. I. – Chlebowski, R. T. – Prentice, R., et al.: Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. *J Natl Cancer Inst*, 2011, 103, s. 470–477.
- Phipps, A. I. – Chlebowski, R. T. – Prentice, R., et al.: Body size, physical activity, and risk of triple-negative and estrogen receptor-positive breast cancer. *Cancer Epidemiol Biomarkers Prev*, 2011, 20, s. 454–463.

Testování prediktivních markerů – současný stav

prof. MUDr. Aleš Ryška, Ph.D. Fingerlandův ústav patologie LF UK a FN Hradec Králové

- Lakhani, S. R., et al.: *Breast Tumours WHO Classification of Tumours*. Ženeva, IARC Press, 2019.
- Dowsett, M. – Nielsen, T. O. – A'Hern, R., et al.: Assessment of Ki67 in breast cancer: Recommendations from the International Ki67 in Breast Cancer Working Group. *J Natl Cancer Inst*. 2011, 103, s. 1656–1664.
- Allison, K. H. – Hammond, M. E. – Dowsett, M., et al.: Estrogen and progesterone receptor testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. *Arch Pathol Lab Med*, 2020, 144, s. 545–563.
- Wolff, A. C. – Hammond, M. E. – Hicks, D. G., et al.: American Society of Clinical Oncology; College of American Pathologists: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. *Arch Pathol Lab Med*, 2014, 138, s. 241–256.
- Wolff, A. C. – Hammond, M. E. – Allison, K. H., et al.: Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. *J Clin Oncol*, 2018, 36, s. 2105–2122.
- Sneige, N. – Hess, K. R. – Multani, A. S., et al.: Prognostic significance of equivocal human epidermal growth factor receptor 2 results and clinical utility of alternative chromosome 17 genes in patients with invasive breast cancer: a cohort study. *Cancer*, 2017, 123, s. 1115–1123.
- Giuliano, A. E. – Connolly, J. L. – Edge, S. B., et al.: Breast cancer – major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. *CA Cancer J Clin*, 2017, 67, s. 290–303.
- Penault-Llorca, F. – Radošević-Robin, N.: Ki67 assessment in breast cancer: an update. *Pathology*, 2017, 49, s. 166–171.
- NCCN Clinical practice guidelines – Breast Cancer – Version 5.2020. Dostupné z: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf, vyhledáno 30. 8. 2020.
- Chevallier, B. – Roche, H. – Olivier, J., et al.: Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. *Am J Clin Oncol*, 1993, 16, s. 223–228.

Personalizovaná medicína – budoucnost prediktivního testování u karcinomu prsu

prof. MUDr. Pavel Dundr, Ph.D. Ústav patologie 1. LF UK a VFN, Praha

- Desai, N. V., et al.: Intrinsic molecular subtypes of breast cancers categorized as HER2-positive using an alternative chromosome 17 probe assay. *Breast Cancer Research*, 2018, 20, 75.
- Pascual, T., et al.: A pathology-based combined model to identify PAM50 non-luminal intrinsic disease in hormone receptor-positive HER2-negative breast cancer. *Front Oncol*, 26. 4. 2019, doi.org/10.3389/fonc.2019.00303.
- Cejalvo, J. M., et al.: Intrinsic subtypes and gene expression profiles in primary and metastatic breast cancer. *Cancer Res*, s. 2213–2221.
- Dias, K., et al.: Claudin-low breast cancer: clinical & pathological characteristics. *PLoS One*, 3. 1. 2017, doi.org/10.1371/journal.pone.0168669.
- Litton, J. K. – Burstein, H. J. – Turner, N. C.: Molecular testing in breast cancer. *Society of Clinical Oncology Educational Book* 39. 17. 5. 2019, s. e1–e7.
- Cancer Genome Atlas, Network. Comprehensive molecular portraits of human breast tumours. *Nature*, 2012, 490, s. 61–70.
- Bertucci, F., et al.: Genomic characterization of metastatic breast cancers. *Nature*, 2019, s. 560–564.
- Ciriello, G., et al.: Comprehensive molecular portraits of invasive lobular breast cancer. *Cell*, 2015, s. 506–519.
- Siraj, A. K., et al.: ALK alteration is a frequent event in aggressive breast cancers. *Breast Cancer Res*, 2015, 127.
- Davies, H., et al.: Whole-genome sequencing reveals breast cancers with mismatch repair deficiency. *Cancer Res*, s. 4755–4762.
- Adams, S. – Goldstein, L. J. – Sparano, J. A., et al.: Tumor-infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC). *Oncol Immunol*, 2015, e985930.
- Kolberg-Liedtke, C., et al.: Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC) – a translational analysis of the prospective WSG PlanB trial. *Breast Cancer Res*, 2020, 47.
- Denkert, C., et al.: Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. *J Clin Oncol*, 2015, s. 983–991.
- Denkert, C., et al.: Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. *J Clin Oncol*, 2010, 28, s. 105–113.
- Savas, P., et al.: Clinical relevance of host immunity in breast cancer: from TILs to the clinic. *Nat Rev Clin Oncol*, 2016, 13, s. 228–241.
- Tomioka, N., et al.: The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC). *Breast Cancer*, 2018, 25, s. 34–42.
- Stanton, S. E. – Adams, S. – Disis, M. L.: Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes: a systematic review. *JAMA Oncol*, 2016, 2, s. 1354–1360.
- Salgado, R., et al.: The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. *Ann Oncol*, 2015, 26, s. 259–271.
- Stovgaard, E. S. – Dyhl-Polk, A. – Roslind, A., et al.: PD-L1 expression in breast cancer: expression in subtypes and prognostic significance: a systematic review. *Breast Cancer Research and Treatment*, 2019, 174, s. 571–584.
- Huang, W. – Ran, R. – Shao, B. – Li, H.: Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis. *Breast Cancer Res Treat*, 2019, 178, s. 17–33.
- Noske, A., et al.: Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastatised breast cancer of the German Adjuvant Intergroup Node-positive study. *Eur J Cancer*, 2019, 114, s. 76–88.
- Schmid, P., et al.: Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. *N Engl J Med*, 2018, 379, s. 2108–2121.

Změna pohledu na testování mutací BRCA 1 a BRCA 2 v onkologické praxi

doc. MUDr. Lenka Foretová, Ph.D. Oddělení epidemiologie a genetiky nádorů Masarykova onkologického ústavu, Brno

- Miki, Y. – Swensen, J. – Shattuck-Eidens, D., et al.: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. *Science*, 1994, 266, s. 66–71.
- Wooster, R. – Bignell, G. – Lancaster, J., et al.: Identification of the breast cancer susceptibility gene BRCA2. *Nature*, 1995, 378, s. 789–792.
- Yoshida, K. – Miki, Y.: Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. *Cancer Sci*, 2004, 95, s. 866–871.
- Petráková, K. – Palácová, M. – Schneiderová, M., et al.: Syndrom hereditárního karcinomu prsu a ovarii. *Klin Onkol*, 2016, suppl. 1, s. 14–21.
- NCCN Guidelines Version 3.2019. Hereditary Breast and/or Ovarian Cancer Syndrome. National Comprehensive Cancer Network. Dostupné z: http://www.nccn.org/professionals/physician_gls/pdf_guidelines.asp, vyhledáno 18. 8. 2020.
- Foretová, L. – Navrátilová, M. – Svoboda, M., et al.: Doporučení pro sledování žen se vzácnějšími genetickými příčinami nádorů prsu a ovarii. *Klin Onkol*, 2019, 32, suppl. 2, s. 256–2513.
- Modrá kniha ČOS. 23. aktualizace, 2017, s. 110.
- Soukupova, J., et al.: Validation of CZECANCA (CZEch CAncer paNel for Clinical Application) for targeted NGS-based analysis of hereditary cancer syndromes. *PLoS One*, 2018, 13, s. e0195761.
- Palácová, M.: Karcinom prsu u nosiček mutací v genu BRCA1/2 – léčíme ho jinak? Zaměřeno na systémovou terapii u mutací v genu BRCA1/2. *Klin Onkol*, 2019, 32, suppl.2, s. 2524–2530.
- Ledermann, J. – Harter, P. – Gourley, Ch., et al.: Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. *Lancet Oncol*, 2014, 15, s. 852–861.
- Tung, N. M. – Garber, J. E.: BRCA1/2 testing: therapeutic implications for breast cancer management. *Br J Cancer*, 2018, 119, s. 141–152.
- Robson, M. – Im, S. A. – Senkus, E., et al.: Olaparib for breast cancer in patients with a germline BRCA mutation. *N Engl J Med*, 2017, 377, s. 523–533.
- Golan, T. – Hammel, P. – Reni, M., et al.: Maintenance olaparib for germline BRCA – mutated metastatic pancreatic cancer. *N Engl J Med*, 2019, 381, s. 317–327.

Současné možnosti chirurgické léčby karcinomu prsu

MUDr. Jana Mergancová Chirurgická klinika Nemocnice Pardubického kraje, a. s., Pardubická nemocnice

- 1 Lettre from Frances Burney to her sister Esther about her mastectomy without anaesthetic, 1812. Dostupné z: www.bl.uk/collection-items/, vyhledáno 17. 8. 2020.
- 2 Mergancová, J.: Neoadjuvantní léčba očima chirurga. *Breast Cancer News*, 2018, 8, s. 17–19.
- 3 NOR, SVOD, www.svod.cz.
- 4 Mergancová, J., et al.: Vyšetření sentinelové uzliny u in situ karcinomu prsu. *Rozhl Chir*, 2011, 90, s. 393–396.
- 5 NCCN Guidelines Version 5.2020. *Margin status recommendations for DCIS and invasive breast cancer*. *BINV-F 1 of 2*.
- 6 Mergancová, J., et al.: Možnosti začlenění nehmátných nálezů v prsu – Quantum satis. *Klin Onkol*, 2019, 32, suppl. 1, s. S73.
- 7 Mergancová, J., et al.: Nádorová duplicita v intramamární uzlině. *Onkologie*, 2019, 13, s. 293–296.
- 8 Morton, D. L., et al.: Technical details of intraoperative lymphatic mapping for early stage melanoma. *Arch Surg*, 1992, 127, s. 392–399.
- 9 Michálek, P., et al.: Ultrazvukem naváděné kompartmentové bloky v pooperační analgezií. *Anest Intenziv Med*, 2013, 24, s. 410–418.
- 10 Petru, V., et al.: Chirurgická léčba karcinomu prsu po neoadjuvantní terapii. *Rozhl Chir*, 2020, 99, s. 172–178.
- 11 NCCN guidelines version 5.2020: *Invasive breast cancer. Surgical axillary staging*. *BINV-D*.

Rekonstrukce prsů implantáty

MUDr. Lucie Zárubová | MUDr. Matěj Patzelt Klinika plastické chirurgie, Fakultní nemocnice Královské Vinohrady, Praha

- 1 Coufal, O. – Fait, V., et al.: *Chirurgická léčba karcinomu prsu*. Praha, Grada, 2011.
- 2 Thamm, O. – Christoph, A.: Immediate versus delayed breast reconstruction. *Clinics in Plastic Surgery*, 2017, 45, DOI: 10.1016/j.cps.2017.08.010.
- 3 Isern, A. E. – Tengrup, I. – Loman, N., et al.: Aesthetic outcome, patient satisfaction, and health-related quality of life in women at high risk undergoing prophylactic mastectomy and immediate breast reconstruction. *J Plast Reconstr Aesthet Surg*, 2008, 61, s. 1177–1187.
- 4 Al-Ghazal, S. – Sully, L. – Fallowfield, L., et al.: The psychological impact of immediate rather than delayed breast reconstruction. *Eur J Surg Oncol*, 2000, 26, s. 17–19.
- 5 Berbers, J. – Baardwijk, A. – Houben, R., et al.: Reconstruction: Before or after postmastectomy radiotherapy? A systematic review of the literature. *Eur J Cancer*, 2014, 50, s. 2752–2762.
- 6 Lin, K. – Blechman, A. – Brenin, D.: Implant-based, two-stage breast reconstruction in the setting of radiation injury: an outcome study. *Plast Reconstr Surg*, 2012, 129, s. 817–823.
- 7 Parsa, A. – Jackowe, D. – Johnson, E., et al.: Selection criteria for expander/implant breast reconstruction following radiation therapy. *Hawaii Med J*, 2009, 68, s. 66–68.
- 8 Sisco, M. – Yao, K.: Nipple-sparing mastectomy: A contemporary perspective. *J Surg Oncol*, 2016, 113, s. 883–890.

Adjuvantní radioterapie časného karcinomu prsu v roce 2020

doc. MUDr. Renata Soumarová, Ph.D. | MUDr. Lenka Rušinová Radioterapeutická a onkologická klinika FN KV a 3. LF UK, Praha

- 1 Darby, S. – McGale, P. – Correa, C., et al.: Trialists' Collaborative Group (EBCTCG): Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. *Early Breast Cancer Lancet*, 2011, 378, s. 1707–1716.
- 2 Bartelink, H. – Maingon, P. – Poortmans, P., et al.: Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. *Lancet Oncol*, 2015, 16, s. 47–56.
- 3 Kunkler, I. H. – Williams, L. J. – Jack, W. J., et al.: Breast-conserving surgery with or without irradiation in women's aged 65 years or older with early breast cancer (PRIME III): a randomised controlled trial. *Lancet Oncol*, 2015, 16, s. 266.
- 4 Ford, H. T. – Coombes, R. C. – Gazet, J. C., et al.: Long-term follow-up of a randomised trial designed to determine the need for irradiation following conservative surgery for the treatment of invasive breast cancer. *Ann Oncol*, 2006, 17, s. 401.
- 5 Dostupné z: <https://clinicaltrials.gov/ct2/show/NCT02400190>, vyhledáno 1. 7. 2020.
- 6 Dostupné z: <https://clinicaltrials.gov/ct2/show/NCT01791829>, vyhledáno 1. 7. 2020.
- 7 Dostupné z: <https://www.clinicaltrials.gov/ct2/show/NCT02653755>, vyhledáno 1. 7. 2020.
- 8 Smith, B. D. – Bellon, J. R. – Blitzblau, R., et al.: Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline. *Pract Radiat Oncol*, 2018, 8, s. 145.
- 9 Hickey, B. E. – James, M. L. – Lehman, M., et al.: Fraction size in radiation therapy for breast conservation in early breast cancer. *Cochrane Database Syst Rev*, 2016, 7, CD003860.
- 10 Haviland, J. S. – Owen, J. R. – Dewar, J. A., et al.: The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. *Lancet Oncol*, 2013, 14, s. 1086.
- 11 Kirby, A. M.: Updated ASTRO Guidelines on Accelerated Partial Breast Irradiation (APBI): To whom can we offer APBI outside a clinical trial? *Br J Radiol*, 2018, 91, s. 20170565.
- 12 Whelan, T. J. – Julian, J. A. – Berrang, T. S., et al.: External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. *Lancet*, 2019, 394, s. 2165.
- 13 Strnad, V. – Ott, O. J. – Hildebrandt, G., et al.: 5-year results of accelerated partial breast irradiation using sole interstitial multicam the ter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. *Lancet*, 2016, 387, s. 229.
- 14 Albert, J. M. – Pan, I. W. – Shih, Y. C., et al.: Effectiveness of radiation for prevention of mastectomy in older breast cancer patients treated with conservative surgery. *Cancer*, 2012, 118, s. 4642.
- 15 Vaidya, J. S. – Wenz, F. – Bulsara, M., et al.: Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. *Lancet*, 2014, 383, s. 603.
- 16 Poortmans, P. M. – Collette, S. – Kirkove, C., et al.: European Organisation for Research and Treatment of Cancer: Internal mammary and medial supraclavicular irradiation in breast cancer. *N Engl J Med*, 2015, 373, s. 317.
- 17 Whelan, T. J. – Olivetto, I. A. – Parulekar, W. R., et al.: Regional nodal irradiation in early-stage breast cancer. *N Engl J Med*, 2015, 373, s. 307.
- 18 Galimberti, V. – Cole, B. F. – Viale, G., et al.: Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. *Lancet Oncol*, 2018, 19, s. 1385.
- 19 Donker, M. – van Tienhoven, G. – Straver, M. E., et al.: Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981–20203 AMAROS): A randomised, multicentre, open-label, phase 3 non-inferiority trial. *Lancet Oncol*, 2014, 15, s. 1303–1310.
- 20 Brown, L. C. – Diehn, F. E. – Boughey, J. C., et al.: Delineation of supraclavicular target volumes in breast cancer radiation therapy. *Int J Radiat Oncol Biol Phys*, 2015, 92, s. 642–649.
- 21 Offersen, B. V. – Boersma, L. J. – Kirkove, C., et al.: ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer, version 1.1. *Radiation Oncol*, 2016, 118, s. 205–208.
- 22 Merzenich, H. – Blettner, M. – Niehoff, D., et al.: Cardiac late events in German breast cancer patients: a validation study on the agreement between patient self-reports and information from physicians. *BMC Cardiovasc Disord*, 2018, 18, s. 218.
- 23 Cheng, Y. J. – Nie, X. Y. – Ji, C. C., et al.: Long-term cardiovascular risk after radiotherapy in women with breast cancer. *J Am Heart Assoc*, 2017, 6.
- 24 Pedersen, A. N. – Korreman, S. – Nyström, H., et al.: Breathing adapted radiotherapy of breast cancer: Reduction of cardiac and pulmonary doses using voluntary inspiration breath-hold. *Radiation Oncol*, 2004, 72, s. 53–60.
- 25 Qi, X. S. – Hu, A. – Wang, K., et al.: Respiration induced heart motion and indications of gated delivery for left-sided breast irradiation. *Int J Radiat Oncol Biol Phys*, 2012, 82, s. 1605–1611.
- 26 Soumarová, R. – Rušinová, L.: Cardiotoxicity of breast cancer radiotherapy – overview of current results. *Rep Pract Oncol Radiother*, 2020, 25, s. 182–186.
- 27 Halyard, M. Y. – Pisansky, T. M. – Solin, L. J., et al.: Adjuvant radiotherapy (RT) and trastuzumab in stage IIIA breast cancer: Toxicity data from North Central Cancer Treatment Group Phase III trial N9831. *J Clin Oncol*, 2006, 24S, ASCO #523.

Zobrazovací metody v diagnostice karcinomu prsu

MUDr. Regina Šírová Mammacentrum Medicon, Praha

- 1 Lobbes, M. B. – Lalji, U. – Houwers, J., et al.: Contrast-enhanced spectral mammography in patients referred from the breast cancer screening programme. *Eur Radiol*, 2014, 24, s. 1668–1676.
- 2 Jochelson, M. S. – Dershaw, D. D. – Sung, J. S., et al.: Bilateral contrast-enhanced dual-energy digital mammography: feasibility and comparison with conventional digital mammography and MR imaging in women with known breast carcinoma. *Radiology*, 2013, 266, s. 743–751.
- 3 Tabar, L. – Chen, H. – Duffy, S. W., et al.: A novel method for prediction of long-term outcome of women with T1a, T1b, and 10–14 mm invasive cancers: a prospective study. *Lancet*, 2000, 335, s. 429–433.
- 4 Terzakis, J. A.: Detection of calcifications in breast biopsies by scanning electron microscopy. *Ultrastr Pathol*, 1998, 22, s. 181–184.
- 5 Association between Screening Mammography Recall Rate and Interval Cancers in the UK Breast Cancer Service Screening Program: A Cohort Study. *Radiology*, 2018, 288, s. 47–54.
- 6 Tabar, L. – Vitak, B.: Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades. *Radiology*, 2012, <https://doi.org/10.1148/radiol.11110469>.

Neoadjuvantní a adjuvantní terapie u časného HER2 pozitivního karcinomu prsu

MUDr. Adam Paulík Klinika onkologie a radioterapie LF UK a FN Hradec Králové

- 1 Prat, A. – Pascual, T. – Adamo, B.: Intrinsic molecular subtypes of HER2+ breast cancer. *Oncotarget*, 2017, 8, s. 73362–73363.
- 2 von Minckwitz, G. – Huang, C. S. – Mano, M. S., et al.; KATHERINE Investigators: Trastuzumab emtansine for residual invasive HER2-positive breast cancer. *N Engl J Med*, 2019, 380, s. 617–628.
- 3 Early Breast cancer Trialists Collaborative Group (EBCTCG): Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. *Lancet Oncol*, 2018, 19, s. 27–39.
- 4 Rastogi, P. – Anderson, S. J. – Bear, H. D., et al.: Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. *J Clin Oncol*, 2008, 26, s. 778–785.
- 5 Cortazar, P. – Zhang, L. – Untch, M., et al.: Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. *Lancet Oncol*, 2014, 384, s. 164–172.
- 6 Earl, H. M. – Hiller, L. – Dunn, J. A., et al.: Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTEMIS trial. *Ann Oncol*, 2017, 28, s. 1817–1824.
- 7 Lombart-Cussac, A. – Cortés, J. – Paré, L., et al.: HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. *Lancet Oncol*, 2017, 18, s. 545–554.
- 8 Phase II study evaluating HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 and pertuzumab (Dana-Farber Harvard Cancer Center 14-409). Otto Metzgher, přednáška na ASCO Annual Meeting 2019.
- 9 Cortés, J. – Saura, C. – Bellet, M., et al.: HER2 and hormone receptor-positive breast cancer-blocking the right target. *Nat Rev Clin Oncol*, 2011, 8, s. 307–311.
- 10 Harbeck, N. – Gluz, O. – Christgen, M., et al.: De-escalation strategies in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (BC): final analysis of the West German study group adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early BC HER2- and hormone receptor-positive phase II randomized trial—efficacy, safety, and predictive markers for 12 weeks of neoadjuvant trastuzumab emtansine with or without endocrine therapy (ET) versus trastuzumab plus ET. *J Clin Oncol*, 2017, 35, s. 3046–3054.
- 11 Gianni, L. – Eiermann, W. – Semiglazov, V. S., et al.: Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. *Lancet Oncol*, 2010, 375, s. 377–384.
- 12 Schneewiss, A. – Chia, S. – Hickish, T., et al.: Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). *Ann Oncol*, 2013, 24, s. 2278–2284.
- 13 Hurvitz, S. A. – Martin, M. – Jung, K. H., et al.: Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2-positive breast cancer: three-year outcomes from the phase III KRISTINE study. *J Clin Oncol*, 2019, 37, s. 2206–2216.
- 14 Cameron, D., et al.: 11 years follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. *Lancet*, 2017, 389, s. 1195–1205.
- 15 Perez, E. A., et al.: Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCTG N9831. *J Clin Oncol*, 2014, 32, s. 3744.
- 16 Gonzales-Angulo, A. M. – Litton, J. K. – Broglio, K. R., et al.: High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. *J Clin Oncol*, 2009, 27, s. 5700–5706.
- 17 Tolaney, S. M. – Barry, W. T. – Dang, C. T., et al.: Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. *N Engl J Med*, 2015, 372, s. 134–141.
- 18 Tolaney, S. M. – Trippa, L. – Barry, W., et al.: TBCRC 033: A randomized phase II study of adjuvant trastuzumab emtansine (T-DM1) vs paclitaxel (T) in combination with trastuzumab (H) for stage I HER2-positive breast cancer (BC) (ATEMPT) [SABCS abstract G51-05]. *Cancer Res*, 2020, 80, suppl.
- 19 Slamon, D. – Eiermann, W. – Robert, N., et al.; Breast cancer International Research Group: Adjuvant trastuzumab in HER2-positive breast cancer. *N Engl J Med*, 2011, 365, s. 1273–1283.
- 20 Earl, H. M. – Hiller, L. – Vallier, A. L., et al.; PERSEPHONE Steering Committee and Trial Investigators: 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. *Lancet Oncol*, 2019, 393, s. 2599–2612.
- 21 Piccart, M. – Procter, M. – Fumagalli, D., et al.: Interim overall survival analysis of APHINITY (BIG 4-11): A randomized multicenter, double-blind, placebo-controlled trial comparing chemotherapy plus trastuzumab plus pertuzumab versus chemotherapy plus trastuzumab plus placebo as adjuvant therapy in patients with operable HER2-positive early breast cancer [SABCS abstract G51-04]. *Cancer Res*, 2020, 80, suppl.
- 22 Chan, A. – Delalogue, S. – Holmes, F. A., et al.; ExteNET Study Group: Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol*, 2016, 17, s. 367–377.
- 23 Piccart-Gebhart, M. – Holmes, E. – Baselga, J., et al.: Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: results from the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial. *J Clin Oncol*, 2016, 34, s. 1034–1042.
- 24 Harbeck, N. – Im, S. A. – Barrios, C. H., et al.: Primary analysis of KAIFLIN: a phase III study of trastuzumab emtansine (T-DM1) + pertuzumab versus trastuzumab + pertuzumab + taxane, after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC) [ASCO abstract 500]. *J Clin Oncol*, 2020, 38, suppl.

Systemová léčba pokročilého HER2 pozitivního karcinomu prsu

MUDr. Lenka Rušinová | doc. MUDr. Renata Soumarová, Ph.D. Radioterapeutická a onkologická klinika FN KV a 3. LF UK, Praha

- 1 Ross, J. S. – Slodkowska, E. A. – Symmans, W. F., et al.: The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. *Oncologist*, 2009, 14, s. 320–368.
- 2 Baselga, J. – Tripathy, D. – Mendelsohn, J., et al.: Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. *J Clin Oncol*, 1996, 14, s. 737–744.
- 3 Slamon, D. J. – Leyland-Jones, B. – Shak, S., et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *N Engl J Med*, 2001, 344, s. 783–792.
- 4 Roth, J. – Bajaj, P. – Sullivan, S. D., et al.: Survival gains from advances in first-line systemic therapy for HER2 overexpressing metastatic breast cancer in the U.S., 1995–2015. ESMO Congress 2017, Madrid, Španělsko, abstrakt 263P.
- 5 Swain, S. M., et al.: Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. *Lancet Oncol*, 2013, 14, s. 461–471.
- 6 Swain, S. M. – Miles, D., et al.: Pertuzumab, trastuzumab, and docetaxel for metastatic HER2-positive breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo controlled, phase 3 study. *Lancet Oncol*, 2020, 21, s. 519–530.
- 7 Wong, Y. – Raghavendra, A. S. – Hatzis, C., et al.: Long-term survival of de novo stage IV Human Epidermal Growth Receptor 2 (HER2) positive breast cancers treated with HER2-targeted therapy. *Oncologist*, 2019, 24, s. 313–318.
- 8 Lambertini, M. – Ferreira, A. R. – Di Meglio, A., et al.: Patterns of care and clinical outcomes of HER2-positive metastatic breast cancer patients with newly diagnosed stage IV or recurrent disease undergoing first-line trastuzumab-based therapy: a multicenter retrospective cohort study. *Clin Breast Cancer*, 2017, 17, s. 601–610.
- 9 Baselga, J. – Cortés, J. – Im, A. S., et al.: Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. *J Clin Oncol*, 2014, 32, s. 3753–3761.
- 10 Junttila, T. T. – Li, D. – Parsons, K., et al.: Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. *Breast Cancer Res Treat*, 2011, 128, s. 347–356.
- 11 Diéras, V. – Miles, D. – Verma, S., et al.: Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. *Lancet Oncol*, 2017, 18, s. 732–742.
- 12 Krop, I. E. – Kim, S. B. – Gonzalez-Martin, A., et al.: Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. *Lancet Oncol*, 2014, 15, s. 689–699.
- 13 Vici, P. – Pizzuti, L. – Michelotti, A., et al.: A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. *Oncotarget*, 2017, 8, s. 56921–56931.
- 14 Ellis, P. A. – Barrios, C. H. – Eiermann, W., et al.: Phase III, randomized study of trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: primary results from the MARIANNE study. *J Clin Oncol*, 2015, 33, s. 507.
- 15 Derakhshani, R., et al.: Overcoming trastuzumab resistance in HER2-positive breast cancer using combination therapy. *J Cell Physiol*, 2020, 235, s. 3142–3156.
- 16 Rugo, H. S. – Im, S. A. – Wright, G. L. S., et al.: SOPHIA primary analysis: a phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic breast cancer (MBC) after prior anti-HER2 therapies (Tx) [abstract]. *J Clin Oncol*, 2019, 37, 15 suppl., s. 1000.
- 17 Broderick, J. M.: Margetuximab shows clinical benefit over trastuzumab in HER2+ metastatic breast cancer. *Targeted Oncology*, 2019, dostupné z: <https://www.targetedonc.com/conference/sabcs-2019/margetuximab-shows-clinical-benefit-over-trastuzumab-in-her2-metastatic-breast-cancer>, vyhledáno 1. 4. 2020.
- 18 Kunte, S., et al.: Novel HER2 targeted therapies for HER2 positive metastatic breast cancer. *American Cancer Society Cancer*, 2020, 0, s. 1–11.
- 19 Rinnerthaler, G. – Gampenrieder, S. P. – Greil, R.: HER2 directed anti-body-drug-conjugates beyond T-DM1 in breast cancer. *Int J Mol Sci*, 2019, 20, s. 1115.
- 20 Columbus, G.: Trastuzumab deruxtecan receives accelerated approval by FDA for HER2+ breast cancer. *Targeted Oncology*, 2019, vyhledáno 22. 12. 2019.
- 21 Saura, C. – Oliveira, M. – Feng, Y. H., et al.: Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with 2 HER2-directed regimens: findings from the multinational, randomized, phase III NALA trial [abstract]. *J Clin Oncol*, 2019, 37, 15 suppl., s. 2001.
- 22 Berberabe, T.: FDA approves supplemental NDA for neratinib in metastatic HER2-positive breast cancer. *Targeted Oncology*, 2020, vyhledáno 1. 1. 2020.
- 23 Murthy, R. K. – Loi, S. – Okines, A., et al.: Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. *N Engl J Med*, 2020, 382, s. 597–609.
- 24 Broderick, J. M.: FDA approves tucatinib for HER2+ breast cancer. *OncoLive*; 2020. Dostupné z: <https://www.onclive.com/web-exclusives/fda-approves-tucatinib-for-her2-breast-cancer>, vyhledáno 17. 4. 2020.
- 25 Kunte, S. – Abraham, J. – Montero, A. J.: Novel HER2-targeted therapies for HER2-positive metastatic breast cancer. *Cancer*, 28. 7. 2020, doi: 10.1002/cncr.33102, online před tiskem.
- 26 Kreutzfeldt, J. – Rozeboom, B. – Dey, N., et al.: The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies. *Am J Cancer Res*, 2020, 10, s. 1045–1067.

Adjuvantní léčba hormonálně pozitivního HER2 negativního časného karcinomu prsu

MUDr. Katarína Petraková, Ph.D. Klinika komplexní onkologické péče Masarykova onkologického ústavu, Brno

- Anderson, W. F. – Chatterjee, N. – Ershler, W. B., et al.: Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. *Breast Cancer Res Treat*, 2002, 76, s. 27–36.
- Alison, K. H. – Hammond, M. E. H. – Dowsitt, M., et al.: Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guidelines update. *J Clin Oncol*, 2020, 38/12, s. 1346–1366.
- www.svod.cz.
- Early Breast Cancer Trialists' Collaborative Group: Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials. *Lancet*, 2011, 378, s. 771–784.
- Lohrisch, C. – Paltiel, C. – Gelmon, K., et al.: Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer. *J Clin Oncol*, 2006, 24/30, s. 4888–4894.
- Sapner, T. – Torney, D. – Gray, R., et al.: Annual hazard rates of recurrence for breast cancer after primary therapy. *JCO*, 1996, 1, s. 2738–2746.
- Davies, C. – Pan, H. – Godwin, J., et al.: Long-term effect of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of estrogen receptor-positive breast cancer: ATLAS, a randomised trial. *Lancet*, 2013, 381, s. 805–816.
- Gray, R. G. – Rea, D. – Handley, K., et al.: Long-term effect of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6953 women with early breast cancer. *J Clin Oncol*, 2013, 31, suppl. abstrakt 5.
- Davies, C. – Pan, H. – Godwin, J., et al.: Long-term effect of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of estrogen receptor-positive breast cancer: ATLAS, a randomised trial. *Lancet*, 2013, 381, s. 805–816.
- Cuzick, J. – Ambroisine, L. – Davidson, N., et al.: Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. *Lancet*, 2007, 369, s. 1711–1723.
- Pagani, O. – Regan, M. M. – Walley, B. A., et al.: Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. *N Engl J Med*, 2014, 371, s. 107–118.
- Burstein, H. J. – Curigliano, G. – Loibl, S., et al.: Estimating the benefit for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast cancer 2019. *Ann Oncol*, 2019, 30, s. 1541–1557.
- Early Breast Cancer Trialists' Collaborative Group: Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. *Lancet*, 2015, 386, s. 1341.
- Grey, E.: Effect of prolonging adjuvant aromatase inhibitor therapy beyond 5-years on recurrence and cause-specific mortality: an EBCTCG meta-analysis of individual patient data from 12 randomised trials including 24,912 women. In: San Antonio breast cancer symposium; 2018.
- Peto, R. – Davies, G. – Godwin, J., et al.: Early Breast cancer Trialists' Collaborative Group (EBCTCG): Comparison between different polychemotherapy regimens for early breast cancer: meta-analysis of long-term outcome among 100 000 women in 123 randomised trials. *Lancet*, 2012, 379, s. 432–444.
- Nitz, U. – Gluz, O. – Clemens, M., et al.: West German Study Group Plan B Trial: Adjuvant four cycles of epirubicin and cyclophosphamide plus docetaxel versus six cycles of docetaxel and cyclophosphamide in HER2-negative early breast cancer. *J Clin Oncol*, 2019, 37, s. 799–808.
- Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37298 women with early breast cancer in 26 randomised trials. *Lancet*, 2019, 393, s. 1440–1452.
- Sparano, J. A. – Gray, R. J. – Makower, D. F., et al.: Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. *N Engl J Med*, 2018, 379, s. 111–121.
- Cardoso, F. – van't Veer, L. J. – Bogaerts, J., et al.: 70-Gene signature as an aid to treatment decisions in early-stage breast cancer. *N Engl J Med*, 2016, 375, s. 717–729.

Aktuální možnosti léčby HR pozitivního a HER2 negativního metastatického karcinomu prsu

MUDr. Markéta Palácová Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno

- Pritchard, K. I. – Gelmon, K. A. – Rayson, D., et al.: Endocrine therapy for postmenopausal women with hormone receptor-positive HER2 negative advanced breast cancer after progression or recurrence on non-steroidal aromatase inhibitor therapy: A Canadian consensus statement. *Curr Oncol*, 2013, 20, s. 48–61.
- Kennecke, H. – Yerushalmi, R. – Woods, R., et al.: Metastatic behaviour of breast cancer subtypes. *J Clin Oncol*, 2010, 28, s. 3271–3277.
- Cardoso, F. – Senkus, E. – Costa, A., et al.: 4rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC4). *An Oncol*, 2018, 29, s. 1634–1657.
- Mehta, R. S. – Barlow, W. E. – Albain, K. S., et al.: Combination anastrozole and fulvestrant in metastatic breast cancer. *N Engl J Med*, 2012, 367, s. 435–444.
- Bergh, J. – Jonsson, P. E. – Lidbrink, E. K., et al.: FACT: an open label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. *J Clin Oncol*, 2012, 30, s. 1919–1925.
- Johnston, S. R., et al.: Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. *Lancet Oncol*, 2013, 14, s. 989–998.
- Robertson, J. F. R. – Bondarenko, I. M. – Trishkina, E., et al.: Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. *Lancet*, 2016, 388, s. 2997–3005.
- Finn, R. S. – Martin, M. – Rugo, H. S., et al.: Palbociclib and letrozole in advanced breast cancer. *N Engl J Med*, 2016, 375, s. 1925–1936.
- Cristofanilli, M. – Turner, N. C. – Bondarenko, I., et al.: Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): Final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. *Lancet Oncol*, 2016, 17, s. 425–439.
- Hortobagyi, G. N., et al.: Updated results from MONALEESA 2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. *Ann Oncol*, 2018, 29, s. 1541–1547.
- Slamon, D. J., et al.: Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, HER2-negative advanced breast cancer: MONALEESA 3. *J Clin Oncol*, 2018, 36, s. 2465–2472.
- Johnson, S. – Martin, M. – di Leo, A., et al.: MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. *NPJ Breast Cancer*, 2019, 5, s. 1–8.
- Goetz, M. P. – Toi, M. – Camponne, M., et al.: MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. *J Clin Oncol*, 2017, 35, s. 3638–3646.
- Sledge, G. W. – Toi, M. – Neven, P., et al.: MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+/HER2– advanced breast cancer who had progressed while receiving endocrine therapy. *J Clin Oncol*, 2017, 25, s. 2875–2886.
- Sledge, G. W. – Toi, M. – Neven, P., et al.: The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, HER2-negative breast cancer that progressed on endocrine therapy – MONARCH 2, a randomized clinical trial. *Jama Oncol*, 2019, 6, s. 116–124.
- Di Leo, A. – O'Shaughnessy, J. – Sledge, G. W., et al.: Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy. *NPJ Breast Cancer*, 2018, 4, s. 41.
- Murai, J. – Huang, S. – Das, B. B., et al.: Trapping of PARP1 and PARP2 by clinical inhibitors. *Cancer Res*, 2012, 72, s. 5588–5599.
- Rottenberg, S. – Jaspers, J. E. – Kersbergen, A., et al.: High sensitivity of BRCA1-deficient malignant tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. *Proc Natl Acad Sci USA*, 2008, 105, s. 17079–1784.
- Juvekar, A. – Burga, L. N. – Hu, H., et al.: Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. *Cancer Discov*, 2012, 2, s. 1048–1063.
- Robson, M., et al.: Olaparib for metastatic breast cancer in patients with a Germane BRCA station. *New Eng J Med*, 2017, 377, s. 523–533.
- Robson, M. E. – Tung, N. – Conte, P., et al.: OlympiAD final overall survival and to liability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA station and HER2-negative metastatic breast cancer. *Ann Oncol*, 2019, 30, s. 558–566.
- Litton, J. K. – Rugo, H. S. – Ettl, J., et al.: Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. *N Engl J Med*, 2018, 79, s. 753–763.
- Han, H. S. – Dieras, V. – Robson, M., et al.: Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II trial. *Ann Oncol*, 2018, 29, s. 154–161.
- Barber, L. J. – Sandhu, S. – Chen, L., et al.: Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor. *J Pathol*, 2013, 229, s. 422–429.
- Montoni, A. – Robu, M. – Pouliot, E., et al.: Resistance to PARP-inhibitors in cancer therapy. *Front Pharmacol*, 2013, 4, s. 18.
- Mollon, L. – Aguilar, A. – Anderson, E., et al.: A systematic literature review of the prevalence of PIK3CA mutations and mutation hotspots in HR+/HER2– metastatic breast cancer. *Cancer Res*, 2018, 78, suppl. 13, s. 1207.
- Baselga, J., et al.: Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. *N Engl J Med*, 2012, 366, s. 520–529.
- Kornblum, N., et al.: Randomized phase II trial of fulvestrant plus everolimus or placebo in postmenopausal women with hormone receptor-positive, HER2 negative metastatic breast cancer resistant to aromatase inhibitor therapy: results of PrE0102. *J Clin Oncol*, 2018, 36, s. 1556–1563.
- Bachelot, T. – Bourcier, C. – Croper, C., et al.: Randomized phase II trial of everolimus in combination with tamoxifen in patient with hormone receptor-positive, HER2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. *J Clin Oncol*, 2012, 30, s. 2718–2724.
- Michaloglou, C., et al.: Combined inhibition of mTOR and CDK4/6 is required for optimal blockade of E2F function and long-term growth inhibition in estrogen receptor-positive breast cancer. *Mol Cancer Ther*, 2018, 17, s. 908–920.
- Bardia, A., et al.: Triplet therapy (continuous ribociclib, everolimus, exemestane) in HR+/HER2– advanced breast cancer post progression on a CDK4/6 inhibitor (TRINITY-1): efficacy, safety and biomarker results. *J Clin Oncol*, 2019, 37, s. 116.
- André, F. – Ciruelos, E. – Rubovszky, G., et al.: Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. *N Engl J Med*, 2019, 380, s. 1929–1940.
- Dawson, S. J. – Makretsov, N. – Blows, F. M., et al.: BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. *Br J Cancer*, 2010, 103, s. 668–675.
- Lok, S. W., et al.: A phase I-b dose-escalation and expansion study of the BCL2 inhibitor venetoclax combined with tamoxifen in ER and BCL2-positive metastatic breast cancer. *Cancer Discov*, 2019, 9, s. 349–369.
- Xi, J. – Ma, C. X., et al.: Sequencing endocrine therapy for metastatic breast cancer: what do we do after disease progression on CDK4/6 inhibitor? *Current Oncol Report*, 2020, 22, s. 57.
- Razavi, P. – Chang, T. – Xu, G., et al.: The genomic landscape of endocrine-resistant advanced breast cancer. *Cancer Cell*, 2018, 34, s. 427–438.
- Fribbens, C. – O'Leary, B. – Kilburn, L., et al.: Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer. *J Clin Oncol*, 2016, 34, s. 2961–2968.
- Chandarlapaty, S. – Chen, D. – He, W., et al.: Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: a secondary analysis of the BOLERO 2 clinical trial. *JAMA Oncol*, 2016, s. 1310–1315.
- O'Shaughnessy, J. – Thaddeus, B. – Royce, M.: Everolimus-based combination therapies for HR+, HER2– metastatic breast cancer. *Cancer Treatment Reviews*, 2018, 69, s. 204–214.
- Mateo, J. – Lord, C. J. – Serra, V., et al.: A decade of clinical development of PARP inhibitors in perspective. *An Oncol*, 2019, 30, s. 1437–1447.
- Hamilton, E. – Infante, J. R.: Targeting CDK4/6 in patients with cancer. *Cancer Treat Rev*, 2016, 45, s. 129–138.

Léčba časného triple negativního karcinomu prsu

MUDr. Vlastimila Čmejlová Onkologická klinika 2. LF UK a FN v Motole, Praha

- 1 Lehmann, B. D. – Bauer, J. A. – Chen, X., et al.: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. *J Clin Invest*, 2011, 121, s. 2750–2767.

Novinky v léčbě metastatického triple negativního karcinomu prsu

MUDr. Miloš Holánek Klinika komplexní onkologické péče Masarykova onkologického ústavu, Brno

- 1 den Brok, W. D. – Speers, C. H. – Gondara, L., et al.: Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed. *Breast Cancer Res Treat*, 2017, 161, s. 549–556.
- 2 Bonotto, M. – Gerrata, L. – Poletto, E., et al.: Measures of outcome in metastatic breast cancer: insights from a real-world scenario. *Oncologist*, 2014, 19, s. 608–615.
- 3 Gobbi, E. – Ezzalfani, M. – Dieras, V., et al.: Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. *Eur J Cancer*, 2018, 96, s. 17–24.
- 4 Lehmann, B. D., et al.: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. *J Clin Invest*, 2011, 121, s. 2750–2767.
- 5 Wang, D.-Y., et al.: Molecular stratification within triple-negative breast cancer subtypes. *Scientific Reports*, 2019, 9, s. 1–10.
- 6 Tun, N. M., et al.: Risk of having BRCA1 mutation in high-risk women with triple-negative breast cancer: a meta-analysis. *Clinical Genetics*, 2014, 85, s. 43–48.
- 7 Copson, E., et al.: Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. *Lancet Oncol*, 2018, 19, s. 169–180.
- 8 Alli, E., et al.: Enhanced sensitivity to cisplatin and gemcitabine in BRCA1-deficient murine mammary epithelial cells. *BMC Pharmacol*, 2011, 11, s. 7.
- 9 Bhattacharyya, A., et al.: The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. *J Biol Chemistry*, 2000, 275, s. 23899–23903.
- 10 Kennedy, R. D., et al.: The role of BRCA1 in the cellular response to chemotherapy. *J Natl Cancer Inst*, 2004, 96, s. 1659–1668.
- 11 Nanda, R., et al.: Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. *J Clin Oncol*, 2016, 34, s. 2460.
- 12 Adams, S., et al.: Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. *An Oncol*, 2019, 30, s. 397–404.
- 13 Cortés, J., et al.: KEYNOTE-119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple-negative breast cancer (mTNBC). *An Oncol*, 2019, 30, s. v859–v860.
- 14 Cortés, J., et al.: KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer. *J Clin Oncol*, 2020, 38, suppl., s. 1000.
- 15 Schmid, P., et al.: Atezolizumab in metastatic TNBC (mTNBC): Long-term clinical outcomes and biomarker analyses [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 1–5. 5. 2017, Washington, DC. Philadelphia (PA): AACR; *Cancer Res*, 2017, 77, suppl. 13, abstrakt 2986, doi:10.1158/1538-7445.AM.2017-2986.
- 16 Sylvia, A. J. D. – Hamilton, E. – Pohlmann, P., et al.: Safety and clinical activity of atezolizumab (anti-PDL1) in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer. *J Clin Oncol Off J Am Soc Clin Oncol*, 2016, 34.
- 17 Schmid, P., et al.: Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. *New Eng J Med*, 2018, 379, s. 2108–2121.
- 18 Robson, M., et al.: Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. *New Eng J Med*, 2017, 377, s. 523–533.
- 19 Litton, J. K., et al.: Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. *New Eng J Med*, 2018, 379, s. 753–763.
- 20 Pascual, J. – Turner, N. C.: Targeting the PI3-kinase pathway in triple-negative breast cancer. *An Oncol*, 2019, 30, s. 1051–1060.
- 21 Baselga, J., et al.: Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. *New Eng J Med*, 2012, 366, s. 520–529.
- 22 Kim, S.-B., et al.: Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Oncol*, 2017, 18, s. 1360–1372.
- 23 Schmid, P., et al.: Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: the PAKT Trial. *J Clin Oncol*, 2020, 38, s. 423–433.

Zárodečná mutace BRCA jako nový léčebný cíl

prof. MUDr. Petra Tesařová, CSc. Onkologická klinika 1. LF UK a VFN, Praha

- 1 Lee, J. M. – Ledermann, J. A. – Kohn, E. C.: PARP inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. *Ann Oncol*, 2014, 25, s. 32–40.
- 2 Godet, I. – Gilkes, D. M.: BRCA1 and BRCA2 mutations and treatment strategies for breast cancer. *Integr Cancer Sci Ther*, 2017, 4, s. 10.15761.
- 3 Ghossaini, M. – Pharoah, P. D. – Easton, D. F.: Inherited genetic susceptibility to breast cancer: the beginning of the end or the end of the beginning? *Am J Pathol*, 2013, 183, s. 1038–1051.
- 4 Pharoah, P. D. – Day, N. E. – Duffy, S., et al.: Family history and the risk of breast cancer: a systematic review and meta-analysis. *Int J Cancer*, 1997, 71, s. 800–809.
- 5 Hall, J. M. – Lee, M. K. – Newman, B., et al.: Linkage of early-onset familial breast cancer to chromosome 17q21. *Science*, 1990, 250, s. 1684–1689.
- 6 Easton, D. F. – Bishop, D. T. – Ford, D., et al.: Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. *Am J Hum Genet*, 1993, 52, s. 678–701.
- 7 Miki, Y. – Swensen, J. – Shattuck-Eidens, D., et al.: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. *Science*, 1994, 266, s. 66–71.
- 8 Stratton, M. R. – Ford, D. – Neuhausen, S., et al.: Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q. *Nat Genet*, 1994, 7, s. 103–107.
- 9 Wooster, R. – Neuhausen, S. L. – Mangion, J., et al.: Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12–13. *Science*, 1994, 265, s. 2088–2090.
- 10 Manickam, K. – Buchanan, A. H. – Schwartz, M. L. B., et al.: Exome sequencing-based screening for BRCA1/2 expected pathogenic variants among adult biobank participants. *JAMA Netw Open*, 2018, 1, s. e182140.
- 11 Albertsen, H. – Plaetke, R. – Ballard, L., et al.: Genetic mapping of the BRCA1 region on chromosome 17q21. *Am J Hum Genet*, 1994, 54, s. 516–525.
- 12 Shattuck-Eidens, D. – McClure, M. – Simard, J., et al.: Collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene implications for presymptomatic testing and screening. *JAMA*, 1995, 273, s. 535–541.
- 13 Ford, D. – Easton, D. F. – Bishop, D. T., et al.: Risks of cancer in BRCA1 mutation carriers. *Lancet*, 1994, 343, s. 692–695.
- 14 Petrucelli, N. – Daly, M. B. – Feldman, G. L.: Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2. *Genet Med*, 2010, 12, s. 245–259.
- 15 Breast Cancer Linkage Consortium: Cancer risks in BRCA2 mutation carriers. *J Natl Cancer Inst*, 1999, 91, s. 1310–1316.
- 16 Foretová, L. – Macháčková, E. – Palácová, M., et al.: Doporučení rozšíření indikačních kritérií ke genetickému testování mutací v genech BRCA1 a BRCA2 u hereditárního syndromu nádorů prsu a ovarií. *Klin Onkol*, 2016, 29, suppl. 1, s. S9–S13.
- 17 Foretová, L. – Navrátilová, M. – Svoboda, M., et al.: Doporučení pro sledování žen se vzácnějšími genetickými příčinami nádorů prsu a ovarií. *Klin Onkol*, 2019, 32, suppl. 2, s. 6–13.
- 18 D'Andrea, A. D.: Mechanisms of PARP inhibitor sensitivity and resistance. *DNA Repair*, 2018, 71, s. 172–176.
- 19 *Modrá kniha České onkologické společnosti*, aktualizace 26, Brno, Masarykův onkologický ústav, 2020.
- 20 Robson, M. – Im, S. A. – Senkus, E., et al.: Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. *N Engl J Med*, 2017, 377, s. 523–533.
- 21 Litton, J. K. – Rugo, H. S. – Ettl, J., et al.: Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. *N Engl J Med*, 2018, 379, s. 753–763.
- 22 Golubeva, V. A. – Nepomuceno, T. C. – Monteiro, A. N. A.: Germline missense variants in BRCA1: new trends and challenges for clinical annotation. *Cancers*, 2019, 11, s. 522.
- 23 Noordermeer, S. M. – van Attikum, H.: PARP inhibitor resistance: a tug-of-war in BRCA-mutated cells. *Trends Cell Biol*, 2019, 29, s. 820–834.
- 24 Gillissen, S. – Bristow, R. G.: The tip of the iceberg: predicting PARP inhibitor efficacy in prostate cancer. *Lancet Oncol*, 2020, 21, s. 17–19.
- 25 Slade, D.: PARP and PARP inhibitors in cancer treatment. *Genes Dev*, 2020, 34, s. 360–394.
- 26 Dostupné z: <https://blog.crownbio.com/parp-inhibitors-2020>, vyhledáno 25. 8. 2020.

Naděje tam, kde nebývala – imunoterapie u metastatického triple negativního karcinomu prsu

prof. MUDr. Jindřich Fínek, Ph.D. Onkologická a radioterapeutická klinika FN a LF UK, Plzeň

- 1 Schmid, P. – Adams, S. – Rugo, S. H., et al.: Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. *N Engl J Med*, 2018, 379, s. 2108–2121.
- 2 Abramson, V. G. – Lehmann, B. D. – Ballinger, T. J., et al.: Subtyping of triple-negative breast cancer: implications for therapy. *Cancer*, 2015, 121, s. 8–16.
- 3 Lehmann, B. D. – Jovanović, B. – Chen, X., et al.: Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. *PLoS ONE*, 2016, 11, e0157368. Dostupné z: <https://doi.org/10.1371/journal.pone.0157368>, vyhledáno 27. 8. 2020.
- 4 Koboldt, D. C. – Fulton, R. – McLellan, M. D., et al.: Comprehensive molecular portraits of human breast tumours. The Cancer Genome Atlas Network. *Nature*, 2012, 490, s. 61–70, DOI: 10.1038/nature11412.
- 5 Wang, C. – Gao, Y. Y. – Pop, I. M., et al.: Measurement and control of quasiparticle dynamics in a superconducting qubit. *Nature Communications*, 2014, 5, 5836.
- 6 Lehmann, B. D. – Bauer, J. A. – Chen, X., et al.: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. *J Clin Invest*, 2011, 121, s. 2750–2767.
- 7 Cimino-Mathews, A. – Thompson, E. – Taube, J. M., et al.: PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. *Hum Pathol*, 2016, 47, s. 52–63.
- 8 Loi, S. – Michiels, S. – Salgado, R., et al.: Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. *Ann Oncol*, 2014, 25, s. 1544–1550.
- 9 Chen, D. S. – Mellman, I.: Oncology meets immunology: the cancer-immunity cycle. *Immunity Review*, 2013, 39, s. 1–10, <http://dx.doi.org/10.1016/j.immuni.2013.07.012>.
- 10 Mittendorf, E. A. – Philips, A. V. – Meric-Bernstam, F., et al.: PD-L1 expression in triple-negative breast cancer. *Cancer Immunol Res*, 2014, 2, s. 361–370, DOI: 10.1158/2326-6066.CIR-13-0127.

- 11 Schmiech, P. – Sdams, S. – Rugo, H. S., et al.: Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. *N Engl J Med*, 2018, 379, s. 2108–2121.
- 12 Emens, L. A. – Adams, S. – Loi, S., et al.: IMpassion130: a Phase III randomized trial of atezolizumab with nab-paclitaxel for first-line treatment of patients with metastatic triple-negative breast cancer (mTNBC). ASCO 2016 (abstrakt TPS1104). *J Clin Oncol*, 2016, 34, suppl. 15, DOI: 10.1200/JCO.2016.34.15_suppl.TPS1104.
- 13 Soliman, H. H.: Nab-paclitaxel as a potential partner with checkpoint inhibitors in solid tumors. *Oncol Targets Ther*, 2017, 10, s. 101–112.
- 14 Luhn, T. – Chui, S. – Hsieh, A., et al.: Comparative effectiveness of nab-paclitaxel monotherapy as first-line (11) treatment of metastatic triple-negative breast cancer (mTNBC) in us clinical practice. ESMO 2018 (abstrakt 2904). *An Oncol*, 2018, 29, suppl. 8, s. viii90–viii121, 10.1093/annonc/mdy272.
- 15 Gradishar, W. J. – Tjulandin, S. – Davidson, N., et al.: Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. *J Clin Oncol*, 2005, 23, s. 7794–803.
- 16 Gradishar, W. J. – Krasnojon, D. – Cheporov, S., et al.: Significantly

longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. *J Clin Oncol*, 2009, 27, s. 3611–3619.

- 17 Schmid, P. – Sdams, S. – Rugo, H. S., et al.: IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC). *J Clin Oncol*, 2019, 37, suppl. 15, s. 1003.

Další možnosti léčby a zlepšení péče o pacientky s hormonálně pozitivním karcinomem prsu – výhled do budoucna

MUDr. Zuzana Bielčíková, Ph.D. Onkologická klinika VFN a 1. LF UK, Praha

- 1 Semiglazov, V. F. – Semiglazov, V. V. – Dashyan, G. A., et al.: Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. *Cancer*, 2007, 10, s. 244–254.
- 2 Smith, I. E. – Dowsett, M. – Ebbs, S. R., et al.: Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. *J Clin Oncol*, 2005, 23, s. 5108–5116.
- 3 Cataliotti, L. – Budzar, A. U. – Noguchi, S., et al.: Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative, Arimidex* Compared to Tamoxifen (PROACT) trial. *Cancer*, 2006, 106, s. 2095–2103.
- 4 Dixon, J. M. – Renshaw, L. – Macaskill, E. J., et al.: Increase in response rate by prolonged treatment with neoadjuvant letrozole. *Br Cancer Res Treat*, 2009, 113, s. 145–151.
- 5 Allevi, G. – Strina, C. – Andreis, D., et al.: Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal estrogen and/or progesterone receptor-positive breast cancer. *Br J Cancer*, 2013, 108, s. 1587–1592.
- 6 Yau, C. – van der Noordaa, M. – Wei, J., et al.: Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer: A multi-center pooled analysis. 2019 San Antonio Breast Cancer Symposium, abstrakt G55-01, prezentováno 13. 12. 2019.
- 7 Prat, A. – Cheang, M. Ch. – Martin, M., et al.: Prognostic significance of progesterone receptor – positive tumor cells within immunohistochemically defined luminal a breast cancer. *J Clin Oncol*, 2013, 31, s. 203–209.
- 8 Prat, A. – Parker, J. S. – Fan, C., et al.: Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. *Ann Oncol*, 2012, 23, s. 2866–2873.
- 9 Cardoso, F. – van't Veer, L. J. – Bogaerts, J., et al.: 70-gene signature as an aid to treatment decisions in early-stage breast cancer. *N Engl J Med*, 2016, 375, s. 717–729.
- 10 Sparano, J. A. – Gray, R. J. – Makower, D. F., et al.: Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. *N Engl J Med*, 2018, 379, s. 111–121.
- 11 Ellis, M. J. – Tao, Y. – Luo, J., et al.: Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristic. *J Natl Cancer Inst*, 2008, 100, s. 1380–1388.
- 12 Provenzano, E. – Bossuyt, V. – Viale, G., et al.: Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group. *Mod Pathol*, 2015, 28, s. 1185–1201.
- 13 von Minckwitz, G. – Huang, Ch. S. – Mano, M. S., et al.: Trastuzumab emtansine for residual invasive HER2-positive breast cancer. *N Engl J Med*, 2019, 380, s. 617–628.
- 14 Robertson, J. – Dowsett, M. – Bliss, J. M., et al.: Peri-operative aromatase inhibitor treatment in determining or predicting longterm outcome in early breast cancer – The POETIC* Trial (CRUK/07/015). *Cancer Res*, 2018, 78, suppl., abstrakt GS1-03.
- 15 Hurvitz, S. A. – Martin, M. – Press, M. F., et al.: Potent cell-cycle inhibition and upregulation of immune response with abemaciclib and anastrozole in neoMONARCH, phase II neoadjuvant study in HR+/HER2 breast cancer. *Clin Cancer Res*, 2020, 26, s. 566–580.
- 16 Johnston, S. – Puhalla, S. – Wheatley, D., et al.: Randomized phase II study evaluating palbociclib in addition to letrozole as neoadjuvant therapy in estrogen receptor-positive early breast cancer: PALLET Trial. *J Clin Oncol*, 2019, 37, s. 178–189.
- 17 Gavila, J. – Saura, C. – Pascual, T., et al.: SOLTI-1402 CORALLEN phase II trial of neoadjuvant ribociclib plus letrozole versus chemotherapy in PAM50 Luminal B early breast cancer: an open-label multicenter, two-arm, randomized study. *SABCS*, 2019, abstrakt GS2-06.
- 18 Whitworth, P. – Beitsch, P. – Mislowsky, A., et al.: Chemosensitivity and endocrine sensitivity in clinical luminal breast cancer patients in the prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) predicted by molecular subtyping. *Ann Surg Oncol*, 2017, 24, s. 669–675.
- 19 Iwata, H. – Masuda, N. – Yamamoto, Y., et al.: Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the Trans NEOS study. *Br Cancer Res Treat*, 2019, 173, s. 123–133.
- 20 Gianni, L. – Zambetti, M. – Clark, K., et al.: Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. *J Clin Oncol*, 2005, 23, s. 7265–7277.
- 21 Chang, J. C. – Makris, A. – Gutierrez, M. C., et al.: Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients. *Breast Cancer Res Treat*, 2008, 108, s. 233–240.
- 22 Yardley, D. A. – Peacock, N. W. – Shastry, M., et al.: A phase II trial of ixabepilone and cyclophosphamide as neoadjuvant therapy for patients with HER2-negative breast cancer: correlation of pathologic complete response with the 21-gene Recurrence Score. *Breast Cancer Res Treat*, 2015, 154, s. 299–308.
- 23 Pivot, X. – Mansi, L. – Chaigneau, L., et al.: In the era of genomics, should tumor size be reconsidered as a criterion for neoadjuvant chemotherapy? *Oncologist*, 2015, 20, s. 344–350.
- 24 Gasol-Cudos, A., et al.: Selection of neoadjuvant treatment based on Oncotype Score in luminal breast cancer. *Breast*, 2019, 44, suppl. 1, abstrakt P166.
- 25 Thekkekkara, L. V., et al.: Predicting response to neoadjuvant chemotherapy in nonmetastatic hormone receptor-positive breast cancer using 21-gene Breast Recurrence Score test. *J Clin Oncol*, 2019, 37, suppl., abstrakt e12093.
- 26 Kantor, O. – Barrera, E. – Koprash, K., et al.: Are we overtreating hormone receptor positive breast cancer with neoadjuvant chemotherapy? Role of OncotypeDx for hormone receptor positive patients undergoing neoadjuvant chemotherapy. *Ann Surg Oncol*, 2019, 26, s. 3232–3239.
- 27 Zelnak, A. B. – Murali, S. – Styblo, T. M., et al.: Phase II trial evaluating the use of 21-gene Recurrence Score to select preoperative therapy in hormone receptor-positive breast cancer. *J Clin Oncol*, 2013, 31, s. 562–562.
- 28 Bear, H. D. – Wan, W. – Robidoux, A., et al.: Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial. *J Surg Oncol*, 2017, 115, s. 917–923.
- 29 Hofmann, D. – Nitz, U. – Gluz, O., et al.: WSG ADAPT – adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial. *Trials*, 2013, 14, s. 261.
- 30 Harbeck, N. – Gluz, O. – Kreipe, H. H., et al.: Abstract P6-05-11: Run-in phase of prospective WSG-ADAPT HR+/HER2- trial demonstrates feasibility of early endocrine sensitivity prediction by recurrence score and conventional parameters in clinical routine. *Cancer Res*, 2013, 73, suppl. 24, abstrakt P6-05-11.
- 31 Hurvitz, S. A. – Martin, M. – Press, M. F., et al.: Potent cell-cycle inhibition and upregulation of immune response with abemaciclib and anastrozole in neoMONARCH, phase II neoadjuvant study in HR+/HER2 breast cancer. *Clin Cancer Res*, 2019, doi: 10.1158/1078-0432.CCR-19-1425.
- 32 Johnston, S. – Puhalla, S. – Wheatley, D., et al.: Randomized phase II study evaluating palbociclib in addition to letrozole as neoadjuvant therapy in estrogen receptor-positive early breast cancer: PALLET Trial. *J Clin Oncol*, 2019, 37, s. 178–189.
- 33 Cottu, P. – D'Hondt, V. – Dureau, S., et al.: Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer. *Ann Oncol*, 2018, 29, s. 2334–2340.
- 34 Marmé, F. – Lederer, B. – Blohmer, J. U., et al.: Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy. *EJC*, 2016, 53, s. 65–74.
- 35 Herrera-Abreu, M. T. – Palafox, M. – Asghar, U., et al.: Early adaptation and acquired resistance to CDK4/6 inhibition in estrogen receptor-positive breast cancer. *Cancer Res*, 2016, 76, s. 2301–2313.
- 36 Jansen, V. M. – Bholra, N. E. – Bauer, J. A., et al.: Kinome-wide RNA interference screen reveals a role for PDK1 in acquired resistance to CDK4/6 inhibition in ER-positive breast cancer. *Cancer Res*, 2017, 77, s. 2488–2499.
- 37 Taylor-Haeding, B. – Aspuria, P. J. – Agadjanian, H., et al.: Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS. *Oncotarget*, 2015, 6, s. 696–714.
- 38 de Leeuw, R. – McNair, Ch. – Schiewer, M. J., et al.: MAPK reliance via acquired CDK4/6 inhibitor resistance in cancer. *Cancer Res*, 2018, 24, s. 4201–4214.
- 39 Gonzalez-Ericsson, P. I. – Estrada, M. V. – Formisano, L., et al.: Abstract PD4-07: Genomic landscape of breast cancers with FGFR1 amplification and FGFR1/CCND1 co-amplification revealed by targeted capture next generation sequencing. *Cancer Res*, 2018, 78, suppl. 4, abstrakt PD4-07.
- 40 Bardia, A. – Hurvitz, S. A. – DeMichele, A., et al.: Triplet therapy (continuous ribociclib, everolimus, exemestane) in HR+/HER2- advanced breast cancer postprogression on a CDK4/6 inhibitor (TRINITI-1): Efficacy, safety, and biomarker results. *J Clin Oncol*, 2019, 37, suppl. 15, s. 1016.
- 41 Rugo, H. S. – Borrego, M. R. – Chia, S. K. L., et al.: Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor-2-negative (HER2-) advanced breast cancer (ABC): First interim BYLieve study results. *J Clin Oncol*, 2019, 37, suppl. 15, s. 1040.
- 42 Jones, R. H. – Casbard, A. – Carucci, M., et al.: Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial. *Lancet Oncol*, 2020, 21, s. 345–357.
- 43 Luen, S. – Virasamy, B. – Savas, P., et al.: The genomic landscape of breast cancer and its interaction with host immunity. *Breast*, 2016, 29, s. 241–250.
- 44 Denkert, C. – von Minckwitz, G. – Darb-Esvahani, S., et al.: Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. *Lancet*, 2018, 19, s. 40–50.
- 45 Muenst, S. – Schaefer, A. R. – Gao, F., et al.: Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. *Breast Cancer Res Treat*, 2014, 146, s. 15–24.
- 46 Basu, G. D. – Ghazalpour, A. – Vader, R., et al.: Abstract P5-04-08: Expression of novel immunotherapeutic targets in luminal breast cancer patients. *Cancer Res*, 2015, 75, suppl. 9, abstrakt P5-04-08.
- 47 Sabatier, R. – Finetti, P. – Mamea, E., et al.: Prognostic and predictive value of PDL1 expression in breast cancer. *Oncotarget*, 2015, 6, s. 5449–5464.
- 48 Ghebem, H. – Mohammed, S. – Al-Omair, A., et al.: The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. *Neoplasia*, 2006, 8, s. 190–198.
- 49 Rugo, H. S. – Delord, J. P. – Im, S. A., et al.: Safety and antitumor activity of pembrolizumab in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer. *Clin Cancer Res*, 2018, 24, s. 2804–2811.
- 50 Dirix, L. Y. – Takacs, I. – Jerusalem, G., et al.: Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. *Breast Cancer Res Treat*, 2018, 167, s. 671–686.
- 51 Tolaney, S. M. – Barroso-Sousa, R. – Keenan, T., et al.: Randomized phase II study of eribulin mesylate (E) with or without pembrolizumab (P) for hormone receptor-positive (HR+) metastatic breast cancer (MBC). *J Clin Oncol*, 2019, suppl. 15, s. 1004.
- 52 Nanda, R. – Liu, M. C. – Yau, Ch., et al.: Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer. An analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial. *JAMA Oncol*, 2020, 6, s. 676–684.
- 53 Schaefer, D. A. – Beckmann, R. P. – Dempsey, J. A., et al.: The CDK4/6 inhibitor abemaciclib induces a T cell inflamed tumor microenvironment and enhances the efficacy of PD-L1 checkpoint blockade. *Cell Reports*, 2018, 22, s. P2978–P2994.

- 54 **Goel, S. – DeCristo, M. J. – Watt, A. C., et al.:** CDK4/6 inhibition triggers anti-tumour immunity. *Nature*, 2017, 548, s. 471–475.
- 55 **Rugo, H. S. – Kabos, P. – Dickler, M. N., et al.:** A phase 1b study of abemaciclib plus pembrolizumab for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC). 2017 San Antonio Breast Cancer Symposium, přednáška P1-09-01.
- 56 **Tolaney, S. M. – Kabos, P. – Dickler, M. N., et al.:** Updated efficacy, safety, & PD-L1 status of patients with HR+, HER2- metastatic breast cancer administered abemaciclib plus pembrolizumab. *J Clin Oncol*, 2018, 36, suppl. 15, s. 1059.
- 57 **Masuda, J. – Tsurutani, J. – Masuda, N., et al.:** Phase II study of nivolumab in combination with abemaciclib plus endocrine therapy in patients with hormone receptor-positive, human epidermal growth factor receptor-2 negative metastatic breast cancer (WJOG11418B, NEWFLAME trial). *Cancer Res*, 2020, 80, suppl. 4, abstrakt OT2-04-07.
- 58 **Provenzano, E. – Bossuyt, V. – Viale, G., et al.:** Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group. *Mod Pathol*, 2015, 28, s. 1185–1201.
- 59 **Coakley, M. – Garcia-Murillas, I. – Turner, N. C.:** Molecular residual disease and adjuvant trials design in solid tumors. *Clin Cancer Res*, 2019, 25, s. 6026–6034.
- 60 **von Minckwitz, G. – Procter, M. – de Azambuja, E., et al.:** Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. *N Engl J Med*, 2017, 377, s. 122–131.

Další možnosti léčby a zlepšení péče o pacienty s HER2 dependentním karcinomem prsu – výhled do budoucna

prof. MUDr. Luboš Petruželka, CSc. Onkologická klinika 1. LF UK VFN a ÚVN, ÚRO NNB, IPVZ, Praha

- NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Breast cancer. Version 4. 2020.
- Swain, S. M. – Miles, D. – Kim, S.-B., et al.:** End-of-study analysis from the phase III, randomized, double-blind, placebo (Pla)-controlled CLEOPATRA study of first-line (1L) pertuzumab (P), trastuzumab (H), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC). *J Clin Oncol*, 2019, 37, suppl., s. 1020–1020.
- Viale, G. – Morganti, S. – Ferraro, E., et al.:** What therapies are on the horizon for HER2 positive breast cancer? *Expert Rev Anticancer Ther*, 2019, 19, s. 811–822.
- Rugo, H. S. – Im, S.-A. – Wright, G. S., et al.:** SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx). *J Clin Oncol*, 2019, 37, suppl., s. 1000–1000.
- Rugo, H. S. – Im, S.-A. – Cardoso, F., et al.:** Phase 3 SOPHIA study of margetuximab + chemotherapy vs trastuzumab + chemotherapy in patients with HER2+ metastatic breast cancer after prior anti-HER2 therapies: second interim overall survival analysis. Prezentováno na: San Antonio Breast Cancer Symposium; 10.–14. 12. 2019; San Antonio, Texas, abstrakt GS1–2, DOI: 10.1158/1538-7445.SABCS19-GS1-02, únor 2020.
- Saura, C. – Oliveira, M. – Feng, Y.-H., et al.:** Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: phase III NALA Trial. *J Clin Oncol*, 2020, 38, s. 3138–3149.
- Murthy, R. K. – Loi, S. – Okines, A., et al.:** Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. *N Engl J Med*, 2020, 382, s. 597–609.
- Modi, S. – Saura, C. – Yamashita, T., et al.:** Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. *N Engl J Med*, 2020, 382, s. 610–621.
- TUKYSA (tucatinib) [prescribing information]. Bethell, W. A., Seattle Genetics, Inc.; Approved 2020. Revised April 2020.
- ENHERTU (fam-trastuzumab deruxtecan-nxki) [prescribing information]. Basking Ridge, NJ: Daiichi Sankyo, Inc.; Approved 2019. Revised December 2019.
- Rugo, H. S. – Im, S.-A. – Wright, G. S., et al.:** SOPHIA primary PFS analysis: a phase 3 study of margetuximab + chemotherapy vs trastuzumab + chemotherapy in patients with HER2+ metastatic breast cancer after prior anti-HER2 therapies. *J Clin Oncol*, 2019, 37 (suppl.): abstrakt 1000, dostupné z: https://www.macrogenics.com/wp-content/wbu-ploads/wb_publications/Rugo-SOPHIA-ASCO-2019-Oral-2019-06-04.pdf, vyhledáno 11. 10. 2020.
- Saura, C. – Oliveira, M. – Feng, Y.-H., et al.:** Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial. *J Clin Oncol*, 2020, 38, s. 3138–3149.
- Murthy, R. – Loi, S. – Okines, A., et al.:** Tucatinib vs placebo, both combined with capecitabine and trastuzumab, for patients with pretreated HER2-positive metastatic breast cancer with and without brain metastases (HER2CLIMB). Program and abstracts of the 2019 San Antonio Breast Cancer Symposium; 10.–14. 12. 2019; San Antonio, Texas, abstrakt GS1–01, DOI: 10.1158/1538-7445.SABCS19-GS1-01, únor 2020.
- Murthy, R. K. – Loi, S. – Okines, A., et al.:** Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. *N Engl J Med*, 2020, 382, s. 597.
- Modi, S. – Andre, F. – Krop, I. E., et al.:** Trastuzumab deruxtecan for HER2-positive metastatic breast cancer: DESTINY-Breast01 subgroup analysis. *J Clin Oncol*, 2020, 38, suppl., s. 1036–1036.
- Pernas, S. – Tolane, S. M.:** HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance. *Ther Adv Med Oncol*, 2019, 11, 1758835919833519, doi: 10.1177/1758835919833519.
- Saura, C. – Oliveira, M. – Feng, Y.-H., et al.:** Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: phase III NALA Trial. ASCO 2019. *J Clin Oncol*, 2020, 38, s. 3138–3149.
- DS-8201a versus T-DM1 for human epidermal growth factor receptor 2 (HER2)-positive, unresectable and/or metastatic breast cancer previously treated with trastuzumab and taxane [DESTINY-Breast03]. ClinicalTrials.gov.NCT03529110.
- Nordstrom, J. L. – Muth, J. – Courtney, L. E., et al.:** High frequency of HER2-specific immunity observed in patients (pts) with HER2+ cancers treated with margetuximab (M), an Fc-enhanced anti-HER2 monoclonal antibody (mAb). *J Clin Oncol*, 2019, 37, suppl., s. 1030–1030.